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Abstract
Background: Pontocerebellar hypoplasia type 6 (PCH6) is a mitochondrial disease caused by mutations in the
RARS2 gene. RARS2 encodes mitochondrial arginyl transfer RNA synthetase, an enzyme involved in mitochondrial
protein translation. A total of 27 patients from 14 families have been reported so far. Characteristic clinical features
comprise neonatal lactic acidosis, severe encephalopathy, intractable seizures, feeding problems and profound
developmental delay. Most patients show typical neuroradiologic abnormalities including cerebellar hypoplasia and
progressive pontocerebellar atrophy.
Methods: We describe the clinical, biochemical and molecular features of 2 siblings with a novel homozygous
mutation in RARS2. Both patients presented neonatally with lactic acidosis. While the older sibling had severe
neurological symptoms with microcephaly, seizures and developmental delay, the younger patient was still
neurologically asymptomatic at the age of 2 months.
Results: MRI studies in both children lacked pontocerebellar involvement. The expression of the OXPHOS complex
proteins was decreased in both patients, whereas oxygen consumption was increased.
Conclusions: Characteristic neuroradiological abnormalities of PCH6 such as vermis and cerebellar hypoplasia and
progressive pontocerebellar atrophy may be missing in patients with RARS2 mutations. RARS2 testing should
therefore also be performed in patients without pontocerebellar hypoplasia but otherwise typical clinical symptoms.
Keywords: Mitochondrial disease, RARS2, Pontocerebellar hypoplasia, OXPHOS, Mitochondrial arginyl transfer RNA
synthetase
Background
Pontocerebellar hypoplasia type 6 (PCH6) is a mitochon-
drial disease with autosomal recessive inheritance caused
by mutations in the RARS2 gene. RARS2 encodes the
mitochondrial arginyl transfer RNA (tRNA) synthetase,
an enzyme which belongs to the group of mitochondrial
aminoacyl tRNA synthetases. These nuclear encoded
mitochondrial proteins play a key role in mitochondrial
protein translation by catalyzing the attachment of
amino acids to their cognate tRNA molecules [1]. De-
fects of mitochondrial aminoacyl tRNA synthetases have
emerged as an important cause of perinatal or infantile
onset respiratory chain disorders with often early fatal
outcome [1]. Mutations in RARS2 were first described in
a consanguineous Sephardic Jewish family [2]. Following
the original description, a total of 27 patients from 14
families have been reported. The typical clinical picture
of PCH6 comprises neonatal lactic acidosis, severe en-
cephalopathy, intractable seizures, hypotonia, spastic
quadriplegia, microcephaly, feeding problems and profound
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developmental delay [2, 3]. Most patients present char-
acteristic neuroradiological abnormalities including cere-
bellar hypoplasia and progressive cerebral cortical atrophy
together with progressive pontocerebellar atrophy [3].
RARS2 mutations are associated with variable oxidative
phosphorylation defects.
We describe the clinical, biochemical and molecular
features of 2 siblings with a novel homozygous mutation
in RARS2. MRI studies in both children lacked pontocer-
ebellar involvement, and the younger patient was still
neurologically asymptomatic at the age of 2 months,
expanding the clinical picture of this disease. A defect of
mitochondrial translation was confirmed in fibroblasts
of both patients. Our cases demonstrate that pontocerebel-
lar hypoplasia (PCH) is no sine qua non for the diagnosis of
RARS2 mutations.
Methods
Patient 1
Sibling 1 is the second son of healthy consanguineous
Saudi Arabian parents (first-degree cousins) with no family
history of metabolic disorders. He was born at term (birth
weight 3100 g, 25th–50th percentile). On the first day
of life he became lethargic and diagnostic work-up re-
vealed metabolic acidosis with mildly elevated lactate. On
day 2 he showed hypoglycemia and signs of infection. At
the age of 3 months he developed muscular hypotonia and
convulsions. Under vigabatrin therapy seizure-frequency
decreased. At the age of 5 months convulsion-pattern
changed and the EEG showed hypsarrythmia as well as a
burst suppression pattern. Consequently, pyridoxine,
folinic acid, biotin and steroids were applied, further
improving frequency and duration of seizures. At the
age of 1, marked motor retardation was evident. On
valproic acid and clobazam supplementation the patient
had only rare seizures since the age of 34 months. At
40 months he was first examined in Germany. A brain
MRI at that age showed mild enlargement of the sub-
arachnoid space, atrophy of both thalami, the mammillary
bodies and of the white matter, but no signs of PCH
(Fig. 1a). A first MRI in Saudi Arabia at the age of
3 months had been normal, a second one at the age of
25 months had shown nearly the same pathologies as the
one in Germany at the age of 40 months. Muscle biopsy at
the same time showed normal histology. Assessment of re-
spiratory chain enzyme activities revealed mild reduction
of the activity of some complexes (Table 1). The electro-
myography was normal. Ophthalmological examination
did not reveal any pathology. Neurotransmitters in CSF
were normal. Comparative genomic hybridization (CGH)
detected no abnormalities. A next-generation-sequencing
panel including 23 nuclear encoded genes involved in
mitochondrial translation yielded a novel homozygous se-
quence variant, c.392T >G; p.(Phe131Cys) in the RARS2
a1 a2
b1 b2
Fig. 1 Brain MRI T2-weighted, sagittal (1) and coronal (2) sections. a Patient 1, microcephaly, mild enlargement of the subarachnoid space and
atrophy of the white matter, but no pontocerebellar hypoplasia at age 40 months. b Patient 2, normal MRI at age 10 days
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gene. This mutation was confirmed by Sanger sequencing.
Both parents were found to be heterozygous for the vari-
ant. At the age of 45 months muscular hypotonia, severe
mental and motor retardation, cerebral visual impairment,
microcephaly and symptomatic epilepsy with continuous
spikes and waves during slow-wave sleep (csws) were seen.
Valproic acid was replaced by Sultiam and methylprednis-
olone pulse therapy was performed, which resulted in
improvement of the EEG and freedom from seizures at
that time.
Patient 2
The girl is the younger sister of patient 1. She was born
at term (birth weight of 2810 g, 10th–25th percentile;
length 49 cm, 25th–50th percentile; head circumference
34 cm, 25th–50th percentile) and showed good postnatal
adaption (Apgar 10/10 at 5 and 10 min, respectively, pH
of cord blood 7.31). On day two she became tachyp-
noeic. Blood gas analysis revealed a severe lactic acidosis
(pH 7.22, bicarbonate -18 mmol/l, pCO2 20 mmHg,
lactate of 22 mmol/l) and hypoglycemia (1.6 mmol/l).
The ammonia concentration in plasma was normal
(78 μmol/l), prothrombin time was 27 % and partial
thromboplastin time 56 s. There were no signs of neo-
natal infection (CRP < 3 mg/l). She received a 10 % dex-
trose infusion, buffering with sodium bicarbonate, fresh
frozen plasma and vitamin K. Because a metabolic dis-
order was suspected she was transferred to the intensive
care unit of our metabolic centre. At arrival she was in a
stable clinical condition without neurological symptoms.
Due to suspected mitochondrial disease, a low-glucose
high-fat infusion (5 g/kg body weight/day and 3 g/kg body
weight/day, respectively) was begun and buffering
with sodium bicarbonate was continued. She was also
started on carnitine (300 mg/d), thiamine (200 mg/d),
riboflavin (100 mg/d) and coenzyme Q10 (50 mg/d).
Within 12 h the lactate concentration normalized
(2.0 mmol/l). On day 3, enteral feeding was initiated.
Initially, the girl received a high-fat diet (50 % breast
milk, 50 % KetoCal 4:1), however, as lactate levels
remained below 5 mmol/l, the child could be fully
breast-fed. At this point, the results of the genetic
panel diagnostics for mitochondrial translation defects
of the older brother became available. As the clinical
picture was well compatible with a RARS2 defect gen-
etic analysis of the RARS2 gene was performed and re-
vealed the same homozygous mutation (c.392T > G;
p.Phe131Cys) as found in her brother. At day 5 an
EEG was perfomed which yielded unremarkable re-
sults. A brain MRI on day 10 showed no abnormal-
ities, especially no signs of PCH or cortical/subcortical
atrophy (Fig. 1b). The metabolic condition remained
stable with lactate concentrations between 1.5–
4.0 mmol/l, and the girl was dismissed from hospital
on day 18 in good clinical condition without any
neurological abnormalities. The supplementation of
coenzyme Q10, riboflavin and thiamin was continued,
the carnitin administration was stopped. During the
following weeks she showed normal weight gain and
stayed neurologically asymptomatic until age 2 months
when the family returned to Saudi Arabia. The results
of RC enzyme expression in fibroblasts as well as the
assessment of oxygen consumption in fibroblasts are
shown in Figs. 2 and 3.
Genetic studies
Next-Generation Sequencing to detect mutations in
all coding exons as well as their flanking intronic re-
gions using DNA-targeted enrichment (SureSelect XT
Target Enrichment; IlluminaR sequencing technology)
was performed. Bioinformatic analysis of collected se-
quencing data was performed by means of BWA Version
0.7.8-r455, SAMtools Version 0.1.19-44428cd, snpEff
Version 3.3f und Alamut-HT Version 1.1.8. Reference
sequence: GRCh37/hg19 assembly. The nomenclature
of sequence variants is in accordance with HGVS rec-
ommendations [4].
Table 1 Enzyme activities of the respiratory chain measured in muscle homogenate of patient 1
[mUnit/mg protein] Reference range [mUnit/mUnit CS] Reference range
Citrate synthase (CS) 168 150–338
Complex I 23 28–76 C1/CS 0.14 0.14–0.35
Complex I + III (C13) 42 49–218 C13/CS 0.25 0.24–0.81
Complex II (C2) 32 33–102 C2/CS 0.19 0.18–0.41
Complex II + III (C23) 45 65–180 C23/CS 0.27 0.30–0.67
Complex III (C3) 327 304–896 C3/CS 1.95 1.45–3.76
Cytochrome oxidase (COX) 201 181–593 COX/CS 1.20 0.91–2.24
Complex V (C5) 69 86–257 C5/CS 0.41 0.42–1.26
Pyruvate dehydrogenase (PDHC) 3.9 5.3–19.8 PDHC/CS 0.023 0.026–0.079
Some enzymes of the respiratory chain showed mildly reduced activities (bold data). However, in relation to the activity of citrate synthase the impairment was
only minimal
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Cell culture
Fibroblasts were obtained from the Newcastle Biobank at
the Institute of Genetic Medicine, Newcastle University.
Informed consent was obtained from all subjects. Fi-
broblasts were grown in high glucose Dulbeccos modified
Eagle’s medium (Sigma, Poole, UK) supplemented with
10 % fetal bovine serum.
Oxygen consumption
Oxygen consumption was measured in adherent fibro-
blasts with a XF96 Extracellular Flux Analyzer (Seahorse
Bioscience Billerica, MA, USA) as described previously
[5]. Each cell line was seeded in 12 wells of a XF96-well
cell culture mircoplate (Seahorse Bioscience) at 30x103
cells/well in 80 μL of DMEM, and incubated for 24 h at
37 °C in a 5 % CO2 atmosphere. After replacing the
growth medium with 180uL of bicarbonate-free DMEM
pre-warmed at 37 °C, cells were pre-incubated for
30 min before starting the assay procedure. Basal res-
piration, proton leak, maximal capacity respiration and
non-electron transport chain respiration were deter-
mined by adding 1 μM oligomycin, carbonyl cyanide-
ptrifluoromethoxyphenylhydrazone (FCCP) (2 injections
of 0.5 μM and 1 μM, respectively) and 1 μM Rotenone/
Antimycin, respectively. The data were corrected by the
NMR and expressed as mol of oxygen/mg of protein. The
quantity of protein was measured by Bradford method [6].
SDS-PAGE
Cells were trypsinised and centrifuged at 1300 rpm for
5 min. The obtained cell pellets were subsequently re-
suspended in 50ul of lysis buffer (1 M Tris-HCl pH7.5,
5 M NaCl, 1 M MgCl2, 10 % Triton X, Protease Inhibitor
(Roche)), vortexed for 30 s every 5 mins (3 times) and sub-
sequently centrifuged at 12.000 rpm for 5 mins. Protein
quantity within the remaining supernatant containing the
cellular extracts was measured by the Bradford method [6].
NuPAGE™ Novex™ 4–12 % Bis-Tris Protein Gels and
NuPAGE® MES SDS Running Buffer (Thermo Fisher
Scientific) were utilized for the pre-cast gel and running
buffer. Electrophoresis and sample preparation were per-
formed according to manufacturer’s instructions. Protein
samples with a final concentration of 20ug/ml were
loaded to each well, and the iBlot® Dry Blotting System
(Thermo Fisher Scientific) was used to transfer the pro-
teins as per the manufacturer’s instructions. Membranes
were incubated for 1 h in blocking buffer (5 % non-fat
milk in TTBS) at room temperature. Three different pri-
mary antibodies were used for detection of the OXPHOS
complexes (Abcam, ab110413, 1:250 dilution), GAPDH
Fig. 2 SDS-PAGE for mitochondrial proteins of the control and 2 patients’ (P1, P2) fibroblast cell lines. P1 and P2 presented decreased levels of
protein expression of the OXPHOS complex proteins. While in P1 the expression of all complexes was severely impaired, in P2 the defect was less
severe and not all complexes were affected
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(Santa Cruz, sc-25778, 1:5000 dilution) and Porin (Abcam,
ab15895, 1:1000 dilution) respectively. The incubation
with the primary antibodies was held overnight at 4 °C.
Clarity™ Western ECL Blotting Substrate (BioRad) and the
Amersham Imager 600 (GE Healthcare Life Sciences)
were used for high-resolution digital imaging of the pro-
tein membranes.
Results
Genetic studies
Next-generation sequencing based analysis identified a
novel homozygous RARS2 missense mutation, c.392T >G;
p.Phe131Cys, in both siblings. This variant has not been ob-
served in sequence analysis of normal individuals or other
patients with suspected PCH6, nor is it represented in the
Single Nucleotide Polymorphism (dbSNP) or ExAc data
base. The predicted amino acid exchange affects a highly
conserved position of the arginyl-tRNA synthetase core
domain. Bioinformatic programs including Alamut-HT
Version 1.1.8, the Sorting Intolerant from Tolerant (SIFT)
and PolyPhen [7, 8] indicated pathogenicity of the amino
acid exchange.
SDS-PAGE
We measured the protein expression levels of the respira-
tory chain complexes. Both patients showed decreased
expression levels of OXPHOS (Fig. 2) compared to the
control. The relative expression of porin, a protein located
in the outer mitochondrial membrane, is significantly de-
creased in Patient1 (p = 0.0084) compared to the control.
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Fig. 3 a/b Oxygen consumption measurement with Seahorse assay. P1 and P2 illustrated increased levels of oxygen consumption, suggesting
compensatory changes
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As a result, CIII and CIV were not detected due to really
low expression levels.
Oxygen consumption
To investigate the mitochondrial defect of the patients’
cell lines we measured the oxygen consumption levels in
primary fibroblasts (Fig. 3). Both patient cell lines showed
slightly increased levels of oxygen consumption in terms
of basal respiration and maximal respiration. Patient 2
presented higher levels of basal and maximal respiration
compared to the control and patient 1. However, none of
the differences is statistically significant. Overall, the in-
creased levels of basal and maximal respiration compared
to the control, in combination with the decreased protein
expression levels of OXPHOS complexes in both patients
may imply the presence of a compensatory mechanism in
fibroblasts.
Discussion
PCH6 due to mutations in the RARS2 gene is a rare
mitochondrial translation defect, and only 29 patients
from 15 families have been reported so far, including the
2 patients in this report. Giving an overview on the first
11 cases, Cassandrini et al. [3] emphasized the exquis-
itely similar clinical phenotype of this genetic disorder.
All patients presented with comparable neurological
symptoms of encephalopathy with intractable seizures
and severe developmental delay. As in other mitochon-
drial diseases, the brain seems to be the most vulnerable
organ. This can be explained by the higher request in
oxidative substrates of the developing brain compared to
other tissues [3]. Other organ manifestations such as
cardiac, ocular, renal or hepatic symptoms are no com-
mon features of this disease. Dysmorphic features are
usually lacking, however, one British girl was described
with a progressive encephalopathy with edema, hypsar-
rhythmia, and optic atrophy (PEHO) -like presentation
including edema of the hands, feet and face as well as facial
abnormalities [9]. The most severe cases were reported by
Lax et al. [1]: Two sisters presented perinatal neurologic
features typical of PCH6 accompanied by cardiomyopathy,
hydrops and pulmonary hypoplasia and died within the first
2 weeks of life. On the other side of the spectrum, Li et al
recently described 2 Hispanic siblings with a rather mild
form of the disease due to a mutation in the promoter of
the RARS2 gene [10]. The older one was reported to have
had normal development until the age of about 6 months.
Similarly, our patient 2 - although she presented with
severe lactic acidosis on the second day of life - was
still neurologically asymptomatic at the age of 2 months
(last follow-up) and therefore displays a rather mild
phenotype. The different clinical severity in patient 1 and
2 underlines the fact that the clinical phenotype cannot
be fully ascribed to the underlying mutations and their
impact on mitochondrial arginyl tRNA synthetase ac-
tivity and the respiratory chain in muscle or fibroblasts
[3, 9, 11]. Phenotypic variability within the same family
has already been mentioned in previous reports [10]
and may be caused by environmental factors, stochastic
events and the genetic background. Different tissue ex-
pression of mitochondrial arginyl tRNA synthetases,
different vulnerability of certain cells with respect to
mitochondrial arginyl tRNA synthetase dysfunction or
yet unknown functions of mitochondrial arginyl tRNA
synthetases, such as involvement in cell signaling, regula-
tion of transcription and splicing, have also been discussed
as possible causes for the clinical heterogeneity [3]. So far,
no asymptomatic individuals have been identified yet, i.e.
by family screening, however, mild or asymptomatic cases
may potentially be underdiagnosed.
The very early onset and severity of symptoms in most
affected patients suggests a prenatal onset of the disease.
This is also confirmed by neuropathologic data which
have been published recently [1]. Post mortem studies of
the brain of 2 twin sisters with RARS2 mutations who
died within the first 2 months of life revealed most pro-
found changes in the cerebellum and in cerebellum-
associated nuclei. These findings lead to the hypothesis
that RARS2 mutations already have small adverse effects
during early embryologic development followed by mid-
gestation developmental slowing or cessation and later
regression in select anatomic regions [12].
The earliest abnormality in patients with RARS2 muta-
tions is usually lactic acidosis due to impairment of the re-
spiratory chain. As in our sibling 2, it may be very
pronounced or even life-threatening during the neonatal
period [1, 9], but usually resolves spontaneously. Detection
of lactic acidosis in a newborn can give an important diag-
nostic hint and may be the only feature suggestive of mito-
chondrial disorder at this age. This is especially important
as lactic acidosis usually becomes less pronounced or even
disappears with older age and may be overlooked. Why
extremely high lactate levels only occur within the first
few days of life remains unclear. Since recurrent metabolic
crises during catabolic episodes triggered by infections as
seen in other mitochondrial disorders have not yet been
described in patients with RARS2 mutations, the neonatal
catabolism is probably not the only reason.
The effects of RARS2 mutations on the respiratory
chain (RC) and the OXPHOS system are variable. While
some patients display severe deficiencies of one or more
RC complexes [1, 3, 11], others have normal enzyme
activities in muscle biopsies [2, 3, 13, 14]. It has been
postulated that disordered mitochondrial messenger
RNA translation may not be the only mechanism of im-
pairment or that a secondary mechanism may exist to
allow some translation [11]. Protein expression of the
OXPHOS complex proteins in our patients was studied
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in fibroblasts and showed decreased expression of multiple
RC enzymes with the defect being much more pronounced
in patient 1. Interestingly, despite lower protein complex
expression in patient cell lines, both basal and maximal res-
piration were higher in patients compared to controls.
These results may imply the presence of a compensatory
mechanism in fibroblasts helping them to function properly
despite the decreased expression of OXPHOS complexes.
Although RC abnormalities in muscle and/or fibroblasts
are helpful in the differential diagnosis if present, they are
not obligatory, and their absence does not rule out PCH6.
The typical neuroimaging findings described in the
first patients identified with RARS2 mutations lead to
the classification of this defect as PCH6. In the majority
of patients MR imaging within the first months of life
already revealed some affection of the pontocerebellum,
ranging from mild vermis cerebellar hypoplasia to pro-
found PCH and gyral immaturity [1, 3, 12]. Normal MRI
findings were reported in only three patients within the
first 2 ½months of life [3, 9, 14], however, in one patient
MR spectroscopy revealed an increased lactate peak.
Two further patients without PCH within the first
4 months of life but otherwise striking abnormalities in-
cluding marked supratentorial atrophy and subdural ef-
fusions have been reported by Kastrissianakis et al. [15].
In both of these siblings cerebellar atrophy occurred
within the first year of life. One patient was already ex-
amined in utero due to an older affected sibling [10].
The prenatal fetal MRI was perfomed at 22 weeks fetal
age and demonstrated no brain abnormalities. The typ-
ical neuroimaging feature in older patients is progressive
cerebral, cerebellar and pontine atrophy, resulting in
marked microcephaly. Therefore, repeat imaging might
reveal the diagnosis where an initial MRI is apparently
normal [9]. In contrast to most other patients reported
to date, patient 1 in this study showed no involvement
of the pontocerebellum at the age of 40 months despite
mild enlargement of the subarachnoid space, atrophy of
both thalami, the mammillary bodies and of the white
matter, demonstrating that cerebellar hypoplasia and at-
rophy may be missing in some patients with PCH6. As
Cassandrini et al. [3] have already emphasized, the usual
lack of basal ganglia involvement is noteworthy for a
metabolic encephalopathy related to a defective OXPHOS
system. Taken together, neither a normal MRI within the
first months of life nor missing pontocerebellar abnormal-
ities within childhood should preclude RARS2 testing in
patients with otherwise suggestive symptoms.
A total of 23 different mutations were reported in the
14 families published to date, including 13 missense
mutations, 7 intronic splite site mutations, 2 deletions
and one mutation in the promoter of RARS2. The only
common mutation which has been found in 3 unrelated
families in heterozygosity is c.35A > G. Rankin et al. [9]
demonstrated that this missense mutation leads to ab-
errant splicing resulting in insertion of part of intron 1
and generation of a premature termination codon. Of
the 27 known cases the majority of 19 patients harbour
compound heterozygous mutations while homozygous
mutations were only detected in three families [2, 10, 16].
The detection of patients from non-consanguineous fam-
ilies with compound heterozygous RARS2 mutations lead
to the hypothesis that this disorder may be more prevalent
than initially recognized [11]. The c.392T >G variant
found in the two siblings of this study has not been de-
scribed before. It affects a highly conserved amino acid
within the core domain of the arginyl tRNA synthase.
Taking into consideration the clinical presentation of
the 2 patients, the biochemical findings and the fact
that the mutation segregates with PCH in the family we
think that the c.392T > G mutation is pathogenic. In
the future, whole exome screening will probably play
an increasing role in the diagnosis of neurodevelop-
mental disorders including metabolic diseases, however,
the rather typical combination of clinical, biochemical
and neuroimaging findings may allow targeted genetic
analysis in the majority of PCH6 patients.
Conclusion
Our cases demonstrate that the characteristic neuroradio-
logical abnormalities of PCH6 such as vermis and cerebel-
lar hypoplasia and progressive pontocerebellar atrophy
may be missing in some individuals, further expanding the
spectrum of RARS2 mutations. The absence of a typical
neuroimaging pattern should not preclude RARS2 testing.
As the nomenclature of PCH6 is misleading, we propose
to replace it by RARS2 mutations.
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